TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the PRU-USA-12 pharmacokinetic trial~* Subject bowels had been cleaned-out (ie, any faecal impactions removed)~* Written informed consent, signed by the subject's legal guardian and by the investigator~* Subject assent documented in the form of a note-to-file in the subject's source documentation~Exclusion Criteria:~• No exclusion criteria

- Gender: None
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: None

Study Arms:
- prucalopride (Type: ACTIVE_COMPARATOR): 0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telerehabilitation Gait Modification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 50 years of age or older~* Exhibit signs of tibiofemoral osteoarthritis based on a score of ≥2 on the Kellgren and Lawrence grading scale predominantly in the medial compartment.~* Self-reported knee pain ≥ 3 / 10 on a numerical rating scale of pain (NRS; 0 = no pain and 10 = worst pain imaginable) during most days of the previous month~* Comfortable walking intermittently for 30 minutes~* Fit into the available sizes of sensor shoes (between US women's 5 to men's 13)~* Exhibits ≥2% reduction in knee adduction moment impulse at 10 degrees of change in toe-in or toe-out during the screening appointment.~Exclusion Criteria:~* Any knee surgery or intraarticular injections within the past 6 months~* A history of joint replacement surgery or high tibial osteotomy~* Current or recent (within 6 weeks) corticosteroid injections~* Use of a gait aid~* Currently on a wait list for joint replacement surgery or high tibial osteotomy~* Any inflammatory arthritic condition~* Any other conditions that may affect normal gait or participation in an aerobic exercise program~* Cannot attend all required appointments

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Intervention: Telerehabilitation (Type: EXPERIMENTAL): Immediate entry into the gait modification intervention delivered using teleconferencing methods
- Delayed Intervention: Telerehabilitation (Type: EXPERIMENTAL): Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of breast cancer established by biopsy.~* Normal kidney function~* Normal LVEF evaluated by MUGA Scan~* \>18 years of age~* Good performance status defined by ECOG scale of 0 or 1~* Consent~* Women of childbearing potential must have a negative pregnancy test.~* Use of effective means of contraception in subjects of child-bearing potential while on treatment and for at least 3 months thereafter.~* Peripheral Neuropathy: must be \< grade 1~* Hematologic (minimal values)~* Absolute neutrophil count \>1,500/mm3~* Hemoglobin \>8.0 g/dl~* Platelet count \>100,000/mm3~* Hepatic~* Total bilirubin \<ULN~* AST, ALT, Alkaline Phosphatase must be within range~Exclusion Criteria:~* Patients with locally advanced breast cancer with skin ulcerations~* Stage IV breast cancer~* Inflammatory breast cancer~* Allergy to any component of the treatment regimen~* Women who are breast feeding~* Pregnancy or refusal to use effective contraception~* Inability to comply with study and/or follow-up procedures.~* Current, recent, or planned participation in a experimental drug study~* Blood pressure of \>150/100 mmHg. Essential hypertension well controlled with anti hypertensives is not an exclusion criterion.~* unstable angina~* New York Heart Association Grade II or greater congestive heart failure~* history of myocardial infarction within 6 months~* history of stroke within 6 months~* Clinical significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastasis~* major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0~* Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days prior to day 0~* Pregnant or lactating~* Urine protein: creatinine ratio \>1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention: Dtx Cyclophosphamide Bev (Type: EXPERIMENTAL): Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has Type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the screening period.~* Patient is receiving a maximum tolerated labeled dose of an ACEi (Angiotensin Converting Enzyme inhibitor) or ARB (Angiotensin II Receptor Blocker)(Renin Angiotensin System (RAS) inhibitor). Estimated GFR (Glomerular Filtration Rate) is greater than or equal to 30 and less than or equal to 75 mL/min/1.73m2 by the CKD (chronic kidney disease)~* Epidemiology Collaboration (EPI) formula.~* UACR (Urinary Albumin to Creatinine Ratio) is greater than or equal to 200 mg/g as determined by the geometric mean of the three morning void urine specimens obtained at Run-in period.~* Serum albumin is greater than or equal to 3.0 g/dL. BNP (B-type Natriuretic Peptide) is less than or equal to 200 pg/mL.~* SBP (Systolic Blood Pressure) is greater than or equal to 110 mmHg and less than or equal to 160 mmHg. HbA1c (Glucosylated Hemoglobin A1c) is less than or equal to 12% and serum potassium is less than or equal to 5.5 mEq/L.~Exclusion Criteria:~* Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to screening.~* Patient is receiving loop diuretics greater than or equal to 120 mg QD (Once Daily) of furosemide or greater than or equal to 3.0 mg QD (Once Daily) of bumetanide or greater than or equal to 150 mg QD (Once Daily) of ethacrynic acid or greater than or equal to 60 mg QD (Once Daily) of torasemide.~* Patient has a documented history of Stage C or Stage D heart failure, defined ACC/AHA (American College of Cardiology/ American Heart Association Practice Guidelines).~* Patient is receiving any of a combination of an ACEi (Angiotensin Converting Enzyme inhibitor) and ARB (Angiotensin II Receptor Blocker) or rosiglitazone or aliskiren or an aldosterone antagonist and patient is receiving pioglitazone and edema is present.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-627, Low dose (Type: EXPERIMENTAL): None
- ABT-627, High dose (Type: EXPERIMENTAL): None
- ABT-627, Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 19 to 55 years of age~* Written informed consent~* Available for all visits and telephone calls scheduled for the study~Exclusion Criteria:~* Previous or suspected disease caused by N. meningitides~* Household and/or intimate exposure to an individual with culture-proven N. meningitides infection within 60 days prior to screening~* Serious acute, chronic or progressive disease as determined by investigator~* History of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- EuNmCV-5 (Type: EXPERIMENTAL): Healthy adults received 0.5mL single intramuscular dose on Day 0.
- Menveo (Type: ACTIVE_COMPARATOR): Healthy adults received 0.5mL single intramuscular dose on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Subjects aged 18 and over who have any of the following diseases~* primary Pulmonary Arterial Hypertension~* secondary Pulmonary Arterial Hypertension caused by connective tissue disease~* \[Phase IIb\] Pulmonary Arterial Hypertension caused by congenital heart disease(including Eisenmenger syndrome)~Exclusion Criteria:~* Subjects with pulmonary arterial hypertension caused by any etiology other than those specified in the inclusion criteria~* BMI(Body Mass Index) \< 18.5kg/m2~* Subjects with hypotension(SBP/DBP\<90/50mmHg) or uncontrolled hypertension(SBP/DBP\>170/100mmHg)~* Creatinine clearance ≤ 30mL/min~* History of non-arteritic anterior ischemic optic neuropathy(NAION)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- udenafil (Type: EXPERIMENTAL): 1. Phase IIa Experimental : Udenafil Dose 1, Dose 2~2. Phase IIb Experimental : Udenafil
- placebo (Type: PLACEBO_COMPARATOR): 1. Phase IIa Placebo Comparator : Placebo~2. Phase IIb Placebo Comparator : Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OTC Mouthpiece for Snoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* Living in the United States~* Signing the Informed Consent Form~Exclusion Criteria:~* Missing teeth (as the device won't be properly fitted)~* Any severe breathing or respiratory disorder, such as chronic asthma, emphysema, COPD, or a similar condition~* Poor dental health, such as severe gum disease, loose teeth, an abscess, mouth sores, or bleeding gums~* A dental implant placed within the last three months~* Diagnosed with a Temporomandibular joint condition (TMJ)~* Actively experiencing any mouth or jaw pain, including clenching of the teeth, grinding, or any other physical injury to the jaw or teeth~* Full dentures~* Braces~* Diagnosis of sleep apnea~* Less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Chelation Therapy (TACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for Participants:~* Heart attack at least 6 weeks prior to study start~Exclusion Criteria for Participants:~* Serum creatinie level greater than 2.0 mg/dL~* Platelet count less than 100,000/µL~* Blood pressure greater than 160/100~* Chelation therapy within 5 years prior to study start~* History of allergic reactions to EDTA or any of the therapy's components~* Coronary or carotid revascularization procedures within 6 months prior to study start or a scheduled revascularization~* Cigarette smoking within 3 months prior to study start~* Childbearing potential~* History of liver disease~* Active heart failure or heart failure hospitalization within 6 months.~* Diagnoses of additional medical conditions that could otherwise limit patient survival~* Inability to tolerate 500-mL infusions weekly.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EDTA + high dose vitamin (Type: ACTIVE_COMPARATOR): Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
- EDTA + high dose vitamin placebo (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
- EDTA placebo + high dose vitamin (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
- EDTA placebo + high dose vitamin placebo (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Typhax, a Typhoid Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men or women who are not pregnant or planning to become pregnant during study duration aged 18 to 55 years.~* Clinical laboratory parameters within normal laboratory limits or not found to be clinically significant by the PI~Exclusion Criteria:~* Relevant history of physical or psychiatric illness or medical disorder that required treatment.~* Known or suspected hypersensitivity to investigational product~* Immunocompromised subjects~* Previous Typhoid vaccination or elevated anti-Vi antibodies at screening~* Known history of Typhoid infection in the previous 6 months~* Positive HIV, HBsAg, or HCV screen~* Any other condition or abnormality that, in the opinion of the Investigator, may compromise the safety of the patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Typhax 0.5 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhax 2.5 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhax 10 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhim Vi 25 mcg (Type: ACTIVE_COMPARATOR): Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
- Placebo (saline) (Type: PLACEBO_COMPARATOR): Placebo control was administered IM Days 0 and 28 ( n=9)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Histologically or cytologically proven IIIB and IV NSCLC.~* No symptomatic uncontrolled brain metastasis~* Not suitable for platinum containing regimens if chemo-naive~* Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale.~* Creatinine Clearance (CrCl) greater than or equal to 45 milliliters per min (mL/min)~Exclusion Criteria~* Prior radiation to greater than 25% of bone marrow~* Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period.~* Presence of clinically relevant third-space fluid collections not controllable.~* Significant cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed - Before Protocol Amendment (Type: EXPERIMENTAL): None
- Pemetrexed - After Protocol Amendment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Managing Neovascular (Known as Wet) Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 50 years of age.~* Active primary subfoveal CNV lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye. Patients with polypoidal choroidal vasculopathy or retinal angiomatous proliferation are eligible to participate in the study, and their condition should be captured in the eCRF.~* ETDRS BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent) in the study eye.~* The area of CNV must occupy at least 50% of the total lesion.~Exclusion Criteria:~* Any prior ocular (in the study eye) or systemic treatment or surgery for nAMD, except dietary supplements or vitamins.~* Any prior or concomitant therapy with another investigational agent to treat nAMD in the study eye.~* Prior treatment with anti-VEGF agents as follows:~* Prior treatment with anti-VEGF therapy in the study eye is not allowed~* Prior treatment with anti-VEGF therapy in the fellow eye with an investigational agent (not approved, e.g. bevacizumab) within the last 3 months before the first dose in the study. Such treatment will also not be allowed during the study. Prior treatment with an approved anti-VEGF therapy in the fellow eye is allowed.~* Prior systemic anti-VEGF therapy, investigational or approved, within the last 3 months before the first dose in the study, and such treatment will not be allowed during the study.~* Total lesion size \>12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by FA in the study eye.~* Subretinal hemorrhages that are either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).~* Scar or fibrosis making up \>50% of the total lesion in the study eye.~* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.~* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early-start T&E / Arm 1 (Type: EXPERIMENTAL): Early-start T\&E arm: test group, early treatment individualization
- Late-start T&E / Arm 2 (Type: ACTIVE_COMPARATOR): Late-start T\&E arm; per label, control group, treatment individualization after Year 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients over 18 years of age~* Locally advanced resectable HER2-positive gastric or esophagogastric junction adenocarcinoma (Sievert types I, II, III)~* Measurable (RECIST criteria) or assessable disease~* ECOG performance 0-2~* Life expectancy of 12 weeks or more~Exclusion Criteria:~* Immeasurable lesion as the only evidence of disease~* Previous chemotherapy or radiotherapy for gastric neoplasm or some kind of previous surgical resection of the tumor (except diagnostic laparoscopy)~* Concomitant heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete